Kyorin Receives Marketing Approval in Japan for `Beova® Tablets 50mg` for the Treatment of Overactive Bladder
(WorldNews Japan)

Kissei Pharmaceutical Co., Ltd. KYORIN Holdings, Inc. Kissei Pharmaceutical Co., Ltd. (Head office: Matsumoto-city, Nagano, Chairman and CEO: Mutsuo Kanzawa, `Kissei`) and KYORIN Holdings, Inc. (Head office: Chiyoda-ku, Tokyo, President & CEO: Minoru Hogawa ) jointly announced today that KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Minoru Hogawa, `Kyorin Pharmaceutical`), a wholly owned subsidiary of KYORIN Holdings, Inc., received approval from the Ministry of Health, Labour and Welfare as of September 21, 2018 to market `Beova® Tablets 50mg` (`Beova® Tablets`) for the treatment of overactive bladder. Kyorin Pharmaceutical signed a license agreement with...